Home Stock

Stock Research: Samsung Biologics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Samsung Biologics

KSC:207940 KR7207940008
23
  • Value
    1
  • Growth
    71
  • Safety
    Safety
    64
  • Combined
    39
  • Sentiment
    24
  • 360° View
    360° View
    23
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Samsung Biologics Co Ltd produces antibody drugs. It operates in the biopharmaceutical industry through its CDMO and Biopharmaceutical Development and Commercialization segments. The company is based in Korea. In the last fiscal year, the company had a market cap of $53,043 million, profits of $1,551 million, and revenue of $3,079 million. The number of employees is unavailable.

more

ANALYSIS: With an Obermatt 360° View of 23 (better than 23% compared with alternatives), overall professional sentiment and financial characteristics for the stock Samsung Biologics are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Samsung Biologics. The consolidated Growth Rank has a good rank of 71, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 71% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 64 which means that the company has a financing structure that is safer than 64% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 1 which means that the share price of Samsung Biologics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 99% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 24, which means that professional investors are more pessimistic about the stock than for 76% of alternative investment opportunities. ...read more

more
Strongest Rank Value
Weakest Rank Profit Growth
Country South Korea
Industry Life Sciences Tools & Services
Size Small
Website samsungbiologics.com
Index
KOSPI
Samsung Biologics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
1 4 8 5
Growth
71 92 51 87
Safety
Safety
64 24 22 24
Sentiment
24 98 84 90
360° View
360° View
23 65 25 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
83 79 80 80
Opinions Change
36 68 60 48
Pro Holdings
n/a 88 36 72
Market Pulse
24 78 87 74
Sentiment
24 98 84 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
1 4 8 5
Growth
71 92 51 87
Safety Safety
64 24 22 24
Combined
39 30 4 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
3 3 3 1
Price vs. Earnings (P/E)
21 3 10 7
Price vs. Book (P/B)
3 10 7 5
Dividend Yield
1 1 1 1
Value
1 4 8 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
76 77 85 86
Profit Growth
92 49 43 86
Capital Growth
19 95 45 14
Stock Returns
48 92 31 77
Growth
71 92 51 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
71 49 39 54
Refinancing
24 6 13 7
Liquidity
78 100 43 37
Safety Safety
64 24 22 24

Similar Stocks

Discover high‑ranked alternatives to Samsung Biologics and broaden your portfolio horizons.

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Youngone

KSC:111770
Country: South Korea
Industry: Apparel, Accessories, Luxury
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews